Company Announcement, Helsinki, 17 April 2026 at 9 AM (EEST)
Nexstim Plc ("Nexstim" or "Company") announces that between 1 October 2025 and 31 March 2026, a total of 21,509 Nexstim Plc’s new shares has been subscribed for with the company's stock options 2020 and 2023. For subscriptions made with the stock options 2020 and 2023, the entire subscription price of EUR 79,742.67 will be entered in the reserve for invested unrestricted equity. The Company’s share capital is EUR 80,000.00 after the subscription.
After the trade registration the total amount of shares is 7,234,896. The new shares represent approximately 0.3 per cent of all the shares in the Company after registration.
The shares subscribed for under the stock options 2020 and 2023 are estimated to be registered in the Trade Register on 24 April 2026. The new shares will establish shareholder rights as of the registration date.
The shares are estimated to be traded in the Nasdaq Helsinki Plc’s First North Growth Market Finland marketplace as an additional lot with the company’s old shares as of 27 April 2026.
The terms and conditions of stock option programs with additional information are available on the company's website at https://www.nexstim.com/investors/.
Further information is available on the website www.nexstim.com, or by contacting:
Leena Niemistö, Chair of Board of Directors
+358 9 2727 170
leena.niemisto@nexstim.com
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the NBS System 6, which is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA-cleared for marketing and commercial distribution for the treatment of Major Depressive Disorder (MDD) in adult and adolescent patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, and as an adjunct for the treatment of adult patients suffering from Obsessive Compulsive Disorder (OCD). In Europe, the NBS 6 system is CE-marked for the treatment of major depression, chronic neuropathic pain as well as post-operative rehabilitation of motor deficits of the upper limb.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com.